Q4 EPS Forecast for Corcept Therapeutics Lifted by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at Zacks Research lifted their Q4 2024 earnings per share (EPS) estimates for Corcept Therapeutics in a note issued to investors on Wednesday, November 20th. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.28 per share for the quarter, up from their prior estimate of $0.26. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q3 2025 earnings at $0.41 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.56 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.38 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. Corcept Therapeutics's revenue for the quarter was up 47.7% compared to the same quarter last year.

CORT has been the subject of a number of other reports. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday, October 31st. Piper Sandler increased their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an "overweight" rating in a report on Wednesday, September 18th. StockNews.com raised shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 31st. Finally, Sandler O'Neill reissued a "buy" rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $65.25.

Corcept Therapeutics Stock Performance

NASDAQ:CORT traded up $1.62 during mid-day trading on Friday, reaching $57.54. The stock had a trading volume of 671,381 shares, compared to its average volume of 1,177,783. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The firm has a market capitalization of $6.03 billion, a price-to-earnings ratio of 44.67 and a beta of 0.45. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $61.66. The business has a 50 day simple moving average of $48.02 and a 200 day simple moving average of $37.65.

Insider Activity at Corcept Therapeutics

In related news, insider Gary Charles Robb sold 11,000 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the sale, the insider now directly owns 22,772 shares in the company, valued at $1,053,888.16. The trade was a 32.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. Insiders sold a total of 36,301 shares of company stock valued at $1,594,253 in the last quarter. Insiders own 20.50% of the company's stock.

Institutional Investors Weigh In On Corcept Therapeutics

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Corcept Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 9,565,782 shares of the biotechnology company's stock valued at $240,962,000 after acquiring an additional 28,250 shares during the period. State Street Corp increased its stake in Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock valued at $162,871,000 after buying an additional 19,893 shares during the period. Dimensional Fund Advisors LP increased its stake in Corcept Therapeutics by 4.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,676,335 shares of the biotechnology company's stock valued at $86,952,000 after buying an additional 108,658 shares during the period. Geode Capital Management LLC increased its stake in Corcept Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company's stock valued at $110,108,000 after buying an additional 99,470 shares during the period. Finally, FMR LLC increased its stake in Corcept Therapeutics by 24.6% in the 3rd quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company's stock valued at $63,122,000 after buying an additional 269,074 shares during the period. Institutional investors and hedge funds own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.